Venetoclax (ABT-199)

For research use only. Not for use in humans.

目录号:S8048 别名: GDC-0199

Venetoclax (ABT-199) Chemical Structure

CAS No. 1257044-40-8

Venetoclax (ABT-199, GDC-0199)是一种Bcl-2选择性抑制剂,无细胞试验中Ki为<0.01 nM,比作用于Bcl-xL和Bcl-w选择性高4800倍以上,对Mcl-1没有抑制活性。有研究证明 Venetoclax 在三阴性乳腺癌 MDA-MB-231 细胞中诱导细胞生长抑制,凋亡,细胞周期停滞和自噬。Phase 3。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 5561.46 现货
RMB 2196.04 现货
RMB 7942.49 现货
RMB 24488.39 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Venetoclax (ABT-199)发表文献370篇:

产品安全说明书

Bcl-2抑制剂选择性比较

生物活性

产品描述 Venetoclax (ABT-199, GDC-0199)是一种Bcl-2选择性抑制剂,无细胞试验中Ki为<0.01 nM,比作用于Bcl-xL和Bcl-w选择性高4800倍以上,对Mcl-1没有抑制活性。有研究证明 Venetoclax 在三阴性乳腺癌 MDA-MB-231 细胞中诱导细胞生长抑制,凋亡,细胞周期停滞和自噬。Phase 3。
特性 ABT-263 (Navitoclax)的重组
靶点
Bcl-2 [1]
(Cell-free assay)
<0.01 nM(Ki)
体外研究

ABT-199 对Bcl-xL, Mcl-1 和Bcl-w具有低的敏感性,Ki分别为48 nM, >444 nM 和 245 nM。ABT-199 有效抑制FL5.12-Bcl-2 细胞, RS4;11细胞, EC50分别为4 nM 和 8 nM,作用于 FL5.12-Bcl-xL细胞具有低活性,EC50为261 nM。ABT-199 诱导RS4;11 细胞快速凋亡,细胞色素c释放,caspase激活,磷脂酰丝氨酸外化,及sub-G0/G1 DNA积累。定量免疫印迹表明,ABT-199对包括NHL,DLBCL,MCL,AML和ALL细胞系的灵敏度,与Bcl-2的表达强烈相关。ABT-199也诱导 CLL 凋亡,平均EC50 为3.0 nM。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
CS-THL1 NFmwUVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1y3Z|IxKG6P Mmq2O|IhcA>? MYXEUXNQ MnXLTY5pcWKrdIOgZ4VtdCCpcn;3eIgh[XO|ZYPz[YQh[nliY3XscEB3cWGkaXzpeJk> MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTlzNk[5PEc,OjV7MU[2PVg9N2F-
CS-THL1 MVHBdI9xfG:2aXOgRZN{[Xl? M4iyWlI2KG6P Ml7XSG1UVw>? NWH6dIdmUW6mdXPld{BieG:ydH;zbZM> MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTlzNk[5PEc,OjV7MU[2PVg9N2F-
DoGKiT M4\6U2Fxd3C2b4TpZ{BCe3OjeR?= NHn4e2w2OCCwTR?= MoPzSG1UVw>? NUfDdI1DUW6mdXPld{BieG:ydH;zbZM> NE\pV3M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUmxOlY6QCd-MkW5NVY3QTh:L3G+
RS4-11 Ml3NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nDbVczKGh? MoOzTWM2OD1yLkC0NFIh|ryP MoHRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4NEm3OlgoRjJ3NkS5O|Y5RC:jPh?=
NALM-6 M{LVWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXkO|IhcA>? M1fy[2lEPTB-MzFOwG0> M3PmOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkS5O|Y5Lz5{NU[0PVc3QDxxYU6=
SU-DHL-6 M3LJdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV[wMlgh|ryP M1S5cmlvcGmkaYTzJINmdGxiZ4Lve5RpKGG|c3Xzd4VlKGK7IHPlcIwhfmmjYnnsbZR6 NGPOSFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW5NFgxOyd-MkW1PVA5ODN:L3G+
OCI-Ly19 MkPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIq1XmQyKM7:TR?= MlTVTY5pcWKrdIOgZ4VtdCCpcn;3eIgh[XO|ZYPz[YQh[nliY3XscEB3cWGkaXzpeJk> NUPK[IZiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1PVA5ODNpPkK1OVkxQDB|PD;hQi=>
SU-DHL-6 MmG1SpVv[3Srb36gRZN{[Xl? MUGwMlc2KM7:TR?= MX:xPEBp Ml\LTY5kemWjc3XzJJBzdy2|dYL2bZZidCCycn;0[YlvKE2FTD2xJIV5eHKnc4Ppc44> M2OzTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUmwPFA{Lz5{NUW5NFgxOzxxYU6=
KCL22 NVnPVlg6TnWwY4Tpc44hSXO|YYm= MVuyJO69VQ>? M3;JOFQ5KGh? M1zn[WROW09? M1n1Smlv[3KnYYPld{BFVkFiZoLh[4Fu\W62YYTpc44> M2\GelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{OzNlUzLz5{NUOzN|I2OjxxYU6=
LOUCY MnLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M164SFExKM7:TR?= M3u1VVQ5KGh? MljuSG1UVw>? M3X0TWlEPTB;MD6wNVM6KM7:TR?= NV;LXI5PRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzNFE4ODRpPkK1N|AyPzB2PD;hQi=>
ALL-SIL M2fL[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;zclExKM7:TR?= MWC0PEBp M3zicWROW09? M3;RcGlEPTB;MD6xPFA{KM7:TR?= NHHnbno9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOwNVcxPCd-MkWzNFE4ODR:L3G+
CUTLL1 NWDrU|RtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkWxNVAh|ryP NXvsUFhSPDhiaB?= MXPEUXNQ NFLhb41KSzVyPUCuN|gzOyEQvF2= M1fGOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{CxO|A1Lz5{NUOwNVcxPDxxYU6=
KOPTK1 Mn20S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYOxNEDPxE1? NEHqS3Q1QCCq NYT0O4p3TE2VTx?= M3O1VmlEPTB;MD62OFMzKM7:TR?= Mly0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV|MEG3NFQoRjJ3M{CxO|A1RC:jPh?=
DND-41 Mn\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWCxNEDPxE1? MWS0PEBp M2XiR2ROW09? MXjJR|UxRTFwOU[5OUDPxE1? MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTNyMUewOEc,OjV|MEG3NFQ9N2F-
PF-382 NXyyfIZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUCxNEDPxE1? MXe0PEBp NYq4RolyTE2VTx?= NF;1XmtKSzVyPUKuNVgzPCEQvF2= NFr1NGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOwNVcxPCd-MkWzNFE4ODR:L3G+
KARPAS-45 MkLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzX[oUyOCEQvF2= MkfpOFghcA>? MlLTSG1UVw>? M1fCUWlEPTB;Mz6yNlI2KM7:TR?= NHHLVoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOwNVcxPCd-MkWzNFE4ODR:L3G+
PEER M2\3[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEO1XI4yOCEQvF2= MkflOFghcA>? NYDjbWJPTE2VTx?= MnjMTWM2OD12Lk[0NFMh|ryP MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTNyMUewOEc,OjV|MEG3NFQ9N2F-
CX-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGG1fmwyODBizszN M2La[|czKGh? NYS3NoRvUUN3ME22Mlch|ryP Mo\OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{MEi4PFIoRjJ3MkC4PFgzRC:jPh?=
LS147T M33YPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jDRVExOCEQvF2= NYjFSGNMPzJiaB?= MY\JR|UxRTJ7LkWg{txO NIDpcnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUKwPFg5Oid-MkWyNFg5QDJ:L3G+
HL-60 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\HSJA2PDhiaB?= NYTPOHR2UUN3MEyxJO69VQ>? M3\LRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{S2NVE3Lz5{NEO0OlEyPjxxYU6=
MOLM-13 M1Tac2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\iVVQ5KGh? M13oXGlEPTB:MTFOwG0> Ml:zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|NE[xNVYoRjJ2M{S2NVE3RC:jPh?=
OCI-AML2 NEXzbVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn71OFghcA>? Mk\kTWM2ODxzIN88US=> NGqxOII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO0OlEyPid-MkSzOFYyOTZ:L3G+
Kasumi-1 NVvFcI45T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYOwTYM6PDhiaB?= MXPJR|UxRDFizszN MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN2NkGxOkc,OjR|NE[xNVY9N2F-
KG-1 Moi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HrOFQ5KGh? MX7JR|UxRDFizszN NWPMU|RIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzOFYyOTZpPkK0N|Q3OTF4PD;hQi=>
THP-1 NHXxWIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUC0PEBp MWrJR|UxRDFizszN NVPLRlN3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzOFYyOTZpPkK0N|Q3OTF4PD;hQi=>
MOLM-14 NX33V2hvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHpVJBZPDhiaB?= M2D0TGlEPTB:MTFOwG0> NVXObnhxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzOFYyOTZpPkK0N|Q3OTF4PD;hQi=>
MOLM-13 NXPKbVZHSXCxcITveIlkKEG|c3H5 NX7vWFlPPTBibl2= MUKyOEBp Mo\uRZBweHSxc3nzJIlv\HWldHnvci=> M2jtUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{S2NVE3Lz5{NEO0OlEyPjxxYU6=
HSB NHfUb4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYCwdnBqOTBizszN M3HJXlQ5KGh? NXTNR406TE2VTx?= MYfJR|UxRTRwNES4JO69VQ>? NF3VSVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO0Nlk1QCd-MkSzOFI6PDh:L3G+
MOLT4 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDEcXJrOTBizszN NX7xcWR4PDhiaB?= MWrEUXNQ NXXIN3RyUUN3ME20MlE2PCEQvF2= NF;POmk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO0Nlk1QCd-MkSzOFI6PDh:L3G+
SKW-3/KE-37 M37TUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\aN2VsOTBizszN M3fze|Q5KGh? NIiycZpFVVOR MW\JR|UxRTBwN{GyJO69VQ>? M3PWSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{SyPVQ5Lz5{NEO0Nlk1QDxxYU6=
SUPT-11 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn[2NVAh|ryP M{W4XFQ5KGh? NX70UWFbTE2VTx?= M1Xa[GlEPTB;ND60O|Mh|ryP Ml3sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|NEK5OFgoRjJ2M{SyPVQ5RC:jPh?=
JURKAT NIDkfnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfmNVAh|ryP Ml\zOFghcA>? NVLlPJRZTE2VTx?= NWrLNms5UUN3ME20Mlg6OyEQvF2= NF\ZeG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO0Nlk1QCd-MkSzOFI6PDh:L3G+
CCRF-CEM NXfmUIVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVqxNEDPxE1? MljzOFghcA>? MWfEUXNQ MX\JR|UxRTFwM{[wJO69VQ>? MoLYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|NEK5OFgoRjJ2M{SyPVQ5RC:jPh?=
LOUCY NEL0R|NCeG:ydH;0bYMhSXO|YYm= NVrETYNROiEQvF2= M2jQN|Q5KGh? MoraSG1UVw>? M3LGXWFxd3C2b4Ppd{BqdmS3Y4Tpc44> MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN2Mkm0PEc,OjR|NEK5OFg9N2F-
RS4:11 MXTDfZRwfG:6aXPpeJkh[XO|YYm= MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTRyN{m3N{c,Ojl2MEe5O|M9N2F-
RS4:11 NXTSO2xMVVSVIHHzd4F6 M4H3d|czKGh? MnzuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{N{izN|MoRjNyMke4N|M{RC:jPh?=
RS4:11 NFXVNXZOXFNiYYPzZZk> MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl{NkK0O{c,Ojh7Mk[yOFc9N2F-
Toledo NITSflBOXFNiYYPzZZk> MnjzO|IhcA>? M2TFS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMke4N|M{Lz5|MEK3PFM{OzxxYU6=
NCI60 MlW4V3JDKGG|c3H5 NIDzelc1QCCq MoTlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7OUS3OlEoRjJ5OUm0O|YyRC:jPh?=
RS4:11 MY\NWHQh[XO|YYm= MkK4NlQhcA>? NE\OS5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS1N|E{PSd-Mkm0OVMyOzV:L3G+
melanoma MkXkV3JDKGG|c3H5 MYq0PEBp NVy1VZcyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5PVQ4PjFpPkK3PVk1PzZzPD;hQi=>
leukemia MnnzV3JDKGG|c3H5 NGCzb5k1QCCq NX;uelB3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5PVQ4PjFpPkK3PVk1PzZzPD;hQi=>
renal cancer NW\BU|c3W1KEIHHzd4F6 NXPlN|l[PDhiaB?= M4\TWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUm0O|YyLz5{N{m5OFc3OTxxYU6=
non-small cell lung cancer NFf0fotUWkJiYYPzZZk> Mn3rOFghcA>? M4rrXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUm0O|YyLz5{N{m5OFc3OTxxYU6=
breast cancer MYjTVmIh[XO|YYm= M1HBeFQ5KGh? NHHNfog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{m5OFc3OSd-Mke5PVQ4PjF:L3G+
colon cancer MUTTVmIh[XO|YYm= MlPnOFghcA>? NXjGPXR5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5PVQ4PjFpPkK3PVk1PzZzPD;hQi=>
ovarian cancer NGjxPZpUWkJiYYPzZZk> MWO0PEBp MlXMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7OUS3OlEoRjJ5OUm0O|YyRC:jPh?=
CNS cancer NUjjbWJ4W1KEIHHzd4F6 NF[5fGE1QCCq M4iwNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUm0O|YyLz5{N{m5OFc3OTxxYU6=
prostate cancer MmrUV3JDKGG|c3H5 NVvwSZY1PDhiaB?= NHrnWGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{m5OFc3OSd-Mke5PVQ4PjF:L3G+
Remb1 MWnNWHQh[XO|YYm= Mnv5NlQhcA>? MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR3M{GzOUc,Ojl2NUOxN|U9N2F-

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Mcl-1 / Bcl-xl / Bcl-2 / Bak / NOXA / Bim; 

PubMed: 30663221     


A549 cells were treated with Ibr-7, ABT-199 or a combination for 2 or 4 h. Total RNA was extracted from A549 cells to undergo RT-qPCR assay.

PARP / Cleaved PARP / Caspase 3 / Cleaved caspase3 / p-S6(Ser236/236); 

PubMed: 30663221     


A549 cells were treated with Ibr-7, ABT-199 or a combination for 24 h before western blotting assay. 

30663221
Growth inhibition assay
Cell death; 

PubMed: 28714472     


The indicated cell lines, treated with 2 μM doxorubicin±1 or 2 μM ABT-199, were quantified by annexin-V staining at 24 h for H2171 and H446 or at 48 h for H196 and SW1271 (mean±s.d., n=3). 

Cell viability; 

PubMed: 29876007     


TNBC cells were cultured with the indicated doses of ABT-199 (μM) for 48 h. 

28714472 29876007
Immunofluorescence
Bcl-2 / Mcl-1; 

PubMed: 28767232     


HEK293T cells cotransfected with the plasmids. Upon transfection, DMSO carrier control, 0.5 μM ABT-199, 10 μM A1210477, or a combination of both 0.5 μM ABT-199 and 10 μM A1210447 were added to the cells. After 30 h, the cells were analyzed for GFP and RFP expression by fluorescence microscopy.

28767232
体内研究 ABT-199 (100 mg/kg)处理RS4;11 移植瘤,产生的最大肿瘤生长抑制率为95%,肿瘤生长延迟152%。ABT-199单独处理或与SDX-105及其他药剂联用处理DoHH2和Granta-519移植瘤,也抑制肿瘤生长。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
- 合并

亲和力分析:

竞争性荧光偏振检测测定ABT-199对Bcl-2家族的不同亚型的亲和力(Ki 或 IC50)。使用如下肽探针/蛋白对:f-bad (1 nM) 与Bcl-xL (6 nM), f-Bax (1 nM) 与 Bcl-2 (10 nM),f-Bax(1 nM) 与Bcl-w (40 nM), f-Noxa(2 nM) 与Mcl-1 (40 nM), 及 f-Bax (1 nM)与Bcl-2-A1(15 nM)。使用时间分辨荧光共振能量转移检测测定对Bcl-xL的亲和力。Bcl-xL (1 nM, His标记的 ) 与200 nM f-Bak, 1 nM Tb标记的anti-His抗体, 及 ABT-199,在室温下混合30分钟。在Envision酶标仪上,使用340/35 nm 激发滤光片及520/525 (f-Bak) 和495/510 nm (Tb标记的anti-His抗体) 发射滤光片,测量荧光值。
细胞实验:[1]
- 合并
  • Cell lines: NHL, DLBCL, MCL, AML 和 ALL 细胞系
  • Concentrations: ~1 μM
  • Incubation Time: 48 小时
  • Method: RS4;11 细胞按每孔5×104个接种在96孔板中,使用初始1 μM-0.05 nM。在半对数期稀释的ABT-199 处理细胞。白血病和淋巴瘤细胞系按每孔1.5-2×104个接种在合适的培养基中,与ABT-199温育48小时。使用Cell TiterGlo 试剂测定对细胞增殖的影响。通过对浓度-反应数据非线性回归分析测定EC50值。
    (Only for Reference)
动物实验:[1]
- 合并
  • Animal Models: 雌性 C.B-17 SCID 小鼠(携带DoHH2 和Granta-519 移植瘤) 和雌性 C.B-17 SCID-beige 小鼠 (携带RS4;11和 Toledo 移植瘤)
  • Dosages: ~100 mg/kg
  • Administration: 口服处理
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 100 mg/mL warmed (115.14 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+50% PEG 300+5% Tween 80+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 868.44
化学式

C45H50ClN7O7S

CAS号 1257044-40-8
储存条件 粉状
溶于溶剂
别名 GDC-0199

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04572763 Not yet recruiting Drug: Copanlisib|Drug: Venetoclax Diffuse Large B Cell Lymphoma|Relapsed Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma Dana-Farber Cancer Institute|AbbVie|Bayer September 2021 Phase 1|Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Could you please offer some advice on the half-life of the drug ?

  • 回答:

    According to the reference (https://www.ncbi.nlm.nih.gov/pubmed/24212376), the half-life of ABT-199 in dogs is 12.9 hr.

  • 问题 2:

    how to prepare the working solution for mice including how to dissolve the powder?

  • 回答:

    We recommend the following vehicle for ABT 199, 30% PEG400/0.5% Tween80/5% Propylene glycol (64.5% water, V/V), at a concentration up to 20mg/ml. Its a homogeneous suspension and can be used for oral gavage.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

相关Bcl-2产品

Tags: 购买Venetoclax (ABT-199) | Venetoclax (ABT-199)供应商 | 采购Venetoclax (ABT-199) | Venetoclax (ABT-199)价格 | Venetoclax (ABT-199)生产 | 订购Venetoclax (ABT-199) | Venetoclax (ABT-199)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID